InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,359.20
(
0.19%
)
Dow Jones
42,124.65
(
0.00%
)
Brent Oil
74.93
(
1.61%
)
Bitcoin
63,492.06
(
0.26%
)
Post# of 29599
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

semi_infinite

Send PM Follow Ignore
Followers 14
Posts 3835
Boards Moderated 1
Alias Born 07/07/2002

semi_infinite

Re: semi_infinite post# 19956

Thursday, 01/23/2020 2:33:43 PM

Thursday, January 23, 2020 2:33:43 PM

Post# of 29599
EYPT - Yutiq (for posterior uveitus) finally booking revenues after some effort. Dexycu (for cataract operation inflammation) showing some early signs of life and has the bigger revenue potential.

http://investors.psivida.com/news-releases/news-release-details/eyepoint-pharmaceuticals-announces-preliminary-fourth-quarter
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up